【摘要】 目的 :观察肝硬化患者肠道菌群的特征 ,探讨调整肠道菌群有效的药物 ,为临床用药提供科学依据。方法 :用细菌显微培养技术和通用引物PCR方法对肝硬化 (试验组 ) 177例和非肝硬化 (对照组 ) 3 0例的肠道菌群进行了细菌鉴定 ,用细菌形态学检测方法观察粪便中细菌的繁殖情况及有无群集现象 ,并比较药物对菌群的影响。结果 :肝硬化组粪便中细菌群集率为 5 1 4% ,明显高于非肝硬化组的 7 8% (P <0 0 1) ;肝硬化组肠道菌群繁殖力、活动能力及对抗生素的耐受力增强。筛选有细菌群集的肝硬化患者 ,分别用培菲康、杜秘克治疗后 ,细菌群集率分别为 60 1%、5 1 2 % ,较安慰剂治疗组为低 (P <0 0 5 )。当两者合用时 ,细菌群集率下降更为显著 (P <0 0 1)。结论 :肝硬化组肠道细菌群集率显著升高。细菌有较强的繁殖能力、活动能力及侵袭力 ,对抗生素耐受力亦增强。杜秘克和培菲康在调整菌群方面较抗生素为优更多还原

【Abstract】 Purpose: To observe the characteristics of intestinal flora in patients with liver cirrhosis and to evaluate the therapeutic effect on these bacteria. Methods: Microculture technique and common primer PCR were employed to identify the features of intestinal flora in 177 patients with liver cirrhosis and 30 healthy controls. The bacterial morphological examination was used to observe the formation and aggregation of bacteria in the stool and several drugs were used to evaluate the therapeutic effect on these bacteria. Results: The aggregation rate of bacteria in the stool was significantly higher in patients with liver cirrhosis than in the healthy controls(51.4% vs 7.8%,P<0 01), furthermore, the generative ability, mobility and resistance to antibiotics remarkably increased in patients with liver cirrhosis. After the patients with liver cirrhosis were treated with bifid triple viable capsule, duphalac and combined both of them, the aggregation rates were 60.1%, 51.2% and 10.7% respectively, significantly decreased as compared with placebo 100%(P<0 05). Conclusion: The aggregation rate of bacteria, the generative ability, activity, resistance to bacteria were significantly higher in patients with liver cirrhosis than in healthy controls. Bifid triple viable capsule and duphalac, as medicine for regulation of the intestinal flora, have better effects than antibiotics.更多还原